Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a cytoplasmic adapter protein and signal transducer that plays a central role in multiple signaling pathways, particularly those involved in immune and inflammatory responses. It functions as an E3 ubiquitin ligase, catalyzing the formation of K63-linked polyubiquitin chains, which serve as scaffolds for recruiting other signaling molecules. TRAF6 is essential for activating downstream signaling cascades, including the NF-kappaB and JNK/MAPK pathways, regulating inflammation, immune responses, cell survival, differentiation, and apoptosis. Mutations or dysregulation in TRAF6 have been linked to several diseases, including Ectodermal Dysplasia A10, Osteopetrosis, immunological disorders, cancer, and inflammation.
Inhibition of TRAF6 E3 ubiquitin ligase activity; disruption of TRAF6 protein-protein interactions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor receptor-associated factor 6 (TRAF6).